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Abstract: Psychiatric disorders represent a heterogeneous class of multifactorial mental diseases
whose origin entails a pathogenic integration of genetic and environmental influences. Incidence
of these pathologies is dangerously high, as more than 20% of the Western population is affected.
Despite the diverse origins of specific molecular dysfunctions, these pathologies entail disruption
of fine synaptic regulation, which is fundamental to behavioral adaptation to the environment.
The synapses, as functional units of cognition, represent major evolutionary targets. Consistently, fine
synaptic tuning occurs at several levels, involving a novel class of molecular regulators known as long
non-coding RNAs (lncRNAs). Non-coding RNAs operate mainly in mammals as epigenetic modifiers
and enhancers of proteome diversity. The prominent evolutionary expansion of the gene number of
lncRNAs in mammals, particularly in primates and humans, and their preferential neuronal expression
does represent a driving force that enhanced the layering of synaptic control mechanisms. In the last
few years, remarkable alterations of the expression of lncRNAs have been reported in psychiatric
conditions such as schizophrenia, autism, and depression, suggesting unprecedented mechanistic
insights into disruption of fine synaptic tuning underlying severe behavioral manifestations of
psychosis. In this review, we integrate literature data from rodent pathological models and human
evidence that proposes the biology of lncRNAs as a promising field of neuropsychiatric investigation.
Keywords: lncRNAs; neuropsychiatric disorders; epigenetics; synaptic function; evolution;
environmental adaptation; homeostasis
1. Neuropsychiatric Disorders: One for All and All for One
Psychiatric illnesses represent a heterogeneous class of diseases. The most common disorders
include major and bipolar depression (MDD and BD), many forms of persistent anxiety (including
obsessive compulsive disorder (OCD), post-traumatic stress syndrome (PTSD), and panic disorders),
addictive disorders, schizophrenia (SCZ), autism spectrum disorders (ASD), intellectual disability
(ID), and attention-deficit/hyperactivity disorder (ADHD). Symptoms include psychosis, delusions,
motivation loss, repetitive behaviors, uncontrolled anxiety, cognitive issues, and dissociation, all of
which translate into severely affected ability to function and live a productive and satisfying life.
Their incidence has grown to worrying percentages, cumulatively reaching 20% of the population
in Western countries. Psychiatric disorders often originate from pathological associations between
a certain genotype, involving susceptibility under the form of multiple detrimental hypomorphic
gene mutations or vulnerability-related Single Nucleotide Polymorphisms (SNPs) and negative
environmental contingencies, grouped together as environmental stressors. The genetic component of
neuropsychiatric disorders emerged from family studies, clearly showing hereditability aspects [1,2].
However, as no clear examples of Mendelian inheritance in mental illness have been provided [1,3],
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it is widely accepted that genetic substrates involve multiple alleles, each contributing with a small
effect, thus defining mental diseases as complex genetic disorders [1,3]. Notably, environmental
stressors thoroughly contribute to these pathologies. This is well documented by the low phenotypic
concordance of neuropsychiatric traits among monozygotic twins, which for SCZ only reaches a rate
of about 50% [4,5]. Accordingly, many studies describe environmental stress as a relevant risk or
triggering factor for mental diseases [2,6–8].
Mental illnesses feature several shared behavioral symptoms, but they also display disease-peculiar
traits that are used to refine their classification. For instance anxiety, a highly common morbidity
experienced by depressed, schizophrenic, and obsessive-compulsive patients, among others, represents
a core behavioral alteration. Similarly, paranoia, cognitive issues, and delusion can be manifested
within a smaller subset of diseases, such as BD and SCZ [9]. Another layer of neuropsychiatric disorder
complexity is represented by alternation of opposite polarity symptoms, as in BD patients, such as
manic or depressive episodes [10].
With this said, as elusive dividing lines characterize different neuropsychiatric disorders in terms
of symptoms association, univocal diagnoses are often difficult to draw [1,3]. Non-trivial behavioral
categorization of mental illness is coupled to other recurrent features displayed by neuropsychiatric
patients, including alternation of symptomatic manifestations with moments of relative normality and
sociality, which again often precipitate following real or perceived negative context or experiences.
Moreover, classification of mental disorders cannot account on objective criteria, as no molecular
and morphostructural correlates have yet been listed as diagnostic biomarkers. Neuropsychiatric
disorders are, therefore, recognized in accordance with International Classification of Disease (ICD)
and Diagnostic and Statistical Manual (DSM) guidelines by arbitrary (though accurate) symptoms and
signs by clinicians. This evidence poses the question of how (and if) to distinguish mental disorders
from one another [9]. A lack of objective diagnostic criteria not only limits mental illness classifications,
but also suggests that a deeper knowledge of molecular and structural endophenotypes (specific,
measurable, and quantifiable biological hallmarks) would represent a fundamental step to reliable
diagnosis and a step forward in disease pathogenesis and future therapies [9].
Interestingly, within heterogeneous mental illness symptomatology, we suggest a unifying origin
under the form of abnormal environmental interaction. Within this domain, it is indeed possible to
identify two specific features: (i) psychiatric patients display aberrant perception of contingencies and
experiences, pathologically arising from an inability to make valid predictions [11,12]; and (ii) psychiatric
patients show severe impairment of environmental adaptability. For example, generalized anxiety
patients are frightened and engage in avoidance-like behaviors following neutral or unthreatening
conditions. In line with this, hallucinations in schizophrenic patients could be seen as an extreme
exacerbation of the described misinterpretation [11]. Regarding the second aspect, impairment of
environmental adaptability, patients suffer from a lack of psychological equilibrium, making them
particularly vulnerable to and modification of their habits. Repetitive behaviors, along with more
complex obsessive manifestations, both result from a stubborn refusal to deviate from routine, regardless
of the environment.
From a biological point of view, our interaction with the environment is mediated at the cellular level
by the synapses. Deciphering the nature of impaired synaptic function, i.e., synaptic endophenotypes [9],
represents a crucial way to increase our knowledge about mental illness pathophysiology.
2. Neuropsychiatric Disorders: Genes and Synaptic Endophenotypes—A Gap to Fill
From the genetic point of view, remarkable convergence has recently been observed within
multiple psychiatric disorders, indicating that similar molecular pathways are involved in different
forms of mental illness, also providing a functional perspective on the above-mentioned overlapping
symptoms [13–16]. One of these studies took advantage of exome sequencing analyses, which were
able to unveil how the same genes and pathways are preferential targets of de novo mutations within
patients of three different disorders—ASD, SCZ, and ID [13]. Gene ontology fell into the categories
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of neuron differentiation, neurogenesis, chromatin modification, and synapse functional modulation.
Another work based on genome-wide association studies (GWAS) provided empirical evidence of
shared genetic etiology for five psychiatric disorders, namely BP, MDD, ADHD, SCZ, and ASD,
providing further evidence of common pathophysiologic mechanisms for these related disorders falling
into the same above-mentioned functional categories [15]. Interestingly, synaptic genes and chromatin
regulators are emerging as pivotal markers in the pathogenesis of mental illness [13,17]. A number of
synaptic genes are indeed targeted by de novo mutations in this set of pathologies, from receptors to
ion channels and scaffolding proteins, including sodium channel SCN2A, the N-methyl-d-aspartate
receptor (NMDAR) subunit GRIN2B, and SHANK genes [16,17]. Additionally, adhesion molecules, such
as neurexin (NRXN) and neuroligin (NLGN), have been reported to play important pathogenic roles
in mental disorders [18]. Interestingly, the family of epigenetic modifiers involved in transcriptional
regulation via chromatin remodeling of synaptic targets is also important in neuropsychiatric disorders.
In this regard, histone demethylases seem to occupy prominent positions; for example, KDM5B and
KDM6B [16,17] together with KDM1A [19] seem to play a part in autism-related symptoms, and notably
represent causative genes for different forms of intellectual disability [20]. It is also interesting to report
the implications of KDM1A in neuropsychiatric-relevant behaviors, such as anxiety, in addition to
learning and memory formation [21–24].
Interestingly, many recent studies based on RNA sequence analyses have highlighted transcriptional
deregulation of long non-coding RNAs (lncRNAs) in the post-mortem brains of psychiatric patients. This
evidence is consistent with recent discoveries, showing that many mutations linked to neuropsychiatric
disorders fall into non-coding regions of the genome. In this context, it is particularly compelling
to underline the growing importance of a new class of non-coding genes, lncRNAs, whose role in
synaptic function (see below) encourages investigation of their role in neuropsychiatric disorders.
Indeed, proper functioning and regulation of synaptic transmission, largely contributed by the
mentioned classes of coding and possibly non-coding genes, is fundamental to adaptive neurophysiology,
which is why alteration of fine synaptic tuning as a substrate of mental illness is a tempting yet
promising hypothesis. Interestingly, fine synaptic tuning not only accounts for cell-autonomous
mechanisms, but also complex circuitry and neuroendocrine-system-related modulation. In the
following paragraphs, we provide a brief description of three known endophenotypes with established
roles in neuropsychiatric disorders, whose potential lncRNA-dependent regulation could reveal
remarkable cues for pathomechanisms, and hence treatment of mental illness.
2.1. HPA Axis Dysfunction
Established theories link synaptic maladaptive plasticity to neuroendocrine dysfunctions, and in
particular to aberrant glucocorticoid metabolism and signaling related to hypothalamic–pituitary–
adrenal (HPA) axis deregulation [25]. As mentioned, stress, particularly when chronically reiterated,
leads to excessive HPA axis stimulation, entailing desensitization of the negative feedback loop, which
is instrumental to stress response termination [26]. Noticeably, such aberrant glucocorticoid signal
transduction causes profound issues in the glutamatergic synapse, having serious detrimental effects
on both axon terminations in terms of aberrant homeostasis of glutamate release, and at the level
of dendritic spines in terms of structural modifications, shrinkage, and decreased density [27,28].
As a matter of fact, stress-induced glucocorticoid disruption participates in the generation of a
psychiatric-like impoverished neurostructural landscape in important brain areas and is widely
recognized to play a fundamental role in mental illness pathogenesis, such as the medial prefrontal
cortex, the amygdala, and the hippocampus [29,30].
2.2. The Endocannabinoid System Disruption
Another interesting synapse-related set of processes likely involved in the pathogenesis of
neuropsychiatric disorders is represented by the endocannabinoid system (ECS) [31–33]. The ECS
is involved in stress response termination as part of a homeostatic mechanism aimed at decreasing
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the amount of stress-elicited neurotransmitter release, in the context of bringing synapse physiology
back to baseline, shutting down anxiety arousal in the meantime. Interestingly, ECS has been shown
to be targeted by chronic stress. Within stress reiteration, indeed endocannabinoid 2-arachidonyl
glycerol (2-AG), the prominent ligand of cannabinoid receptor 1 (CB1), is consistently synthesized
in the post-synapse, causing CB1 desensitization in the pre-synapse and relative loss of control over
neurotransmitter release [34]. This maladaptive pathway represents one of the gateways of emotional
drift shared by most neuropsychiatric disorders. Additionally, 2-AG’s half-life, which is enhanced
upon acute stress by a transcriptional mechanism aimed at decreasing its degrading enzymes MAGL
and ABHD6, is not positively regulated when exposed to chronic stress [35].
2.3. Predictive Sensing Alteration
Brain activity features peculiar default oscillations (including gamma oscillations), whose
synchronization with external stimuli, known as predictive sensing, optimizes environmental
perception, response, and adaptation. Predictive sensing is referred to as a highly dynamic mechanism
entraining default patterns of internal excitability fluctuations to external stimuli, thereby amplifying
inputs related to these stimuli [11,12]. Interestingly, there is substantial agreement about gamma
oscillations and predictive sensing disruption in SCZ [12,36], a process that requires fine synaptic tuning.
As mentioned, the available literature still cannot provide readers with a precise description of
lncRNAs’ biological contribution to the three above-mentioned core endophenotypes of neuropsychiatric
disorders. However, we collected evidence suggesting inherent involvement of lncRNAs in cellular
neurobiology processes, whose emergent properties underlie prototypic neuropsychiatric endophenotypes.
Therefore, to better understand the role of lncRNAs in neuropsychiatric disorders, we suggest the
importance of actually studying their biological relevance from the perspective of aberrant functioning
of HPA axis regulation, the endocannabinoid system, and the process of predictive sensing.
In the next sections we will (i) describe the biology of lncRNAs and then (ii) provide a perspective
on how some of them, in particular GOMAFU, NEAT1, and MALAT1, could play important roles in
synaptic tuning and mental illness.
3. Evolution and Biology of Long Non-Coding RNAs
The application of next-generation sequencing (NGS) technology to transcriptome analysis has
radically changed the way we look at our genome, revealing that what was previously considered
“junk DNA” due to a lack of coding potential is actually actively transcribed, giving rise to thousands
of non-coding RNA transcripts with regulatory roles. It is estimated that more than 80% of the human
genome is actively transcribed but only around 2%–3% is translated into proteins, meaning that the
transcriptional output of our genome is almost monopolized by non-coding RNAs (ncRNAs) [37]. Long
non-coding RNAs represent the most abundant class of ncRNAs in the human genome. The current
GENCODE release (version 33) [38] contains 17,952 lncRNA genes, accounting for 48,438 transcripts,
while the number of lncRNAs annotated by the NONCODE (v5.0) and LNCpidia (version 5.2) databases
rises to 96,308 and 56,946, respectively [39,40]. Remarkably, while the number of protein-coding genes
and corresponding sequences remained surprisingly constant during the evolution of eukaryotic
organisms, the number of lncRNAs dramatically rose with increasing developmental and organ
complexity (Table 1) [41,42]. Similarly, the set of “synaptic genes”, which mechanistically fulfill
neuronal core biological functions, is largely conserved among the different rungs of the evolutionary
ladder, even concerning very simple nervous systems, such as in C. elegans [43]. On the contrary, if we
consider that Homo sapiens holds 8000 additional lncRNAs compared to Mus musculus and that almost
half of them are brain specific [44], we can easily appreciate that among the same class of organisms
(mammals), variability of lncRNAs correlates with increased complexity and brain connectomics [45].
A significant fraction of these newly emerged lncRNAs is involved in transcriptional and epigenetic
control of gene expression, acting on nuclear organization and chromatin states, among other functions.
Thus, it has been hypothesized that lncRNAs had a crucial role in creating the high complexity of the
Int. J. Mol. Sci. 2020, 21, 3030 5 of 19
regulatory mechanisms and networks typical of the most evolved organisms. This is further supported
by the observation that many lncRNAs have more specific expression patterns than coding genes,
especially in the brain [44].
Table 1. Comparison between the number of coding and non-coding lncRNA genes across six different
species, along with their evolution. Note that while the number of coding genes does not increase
along with species complexity, the number of lncRNAs increases considerably. Sources: 1 GENCODE
(https://www.gencodegenes.org/); 2 Ensembl Genome Browser (https://www.ensembl.org/); 3 FlyBase
(https://flybase.org/); 4 Saccharomyces Genome Database (SGD) (https://www.yeastgenome.org/).
LncRNA, long non-coding RNA.
An Emerging Role of lncRNAs in Driving Evolution
Species Number of Protein-Coding Genes Number of lncRNA Genes
Homo sapiens 19.957 (1)–20.449 (2) 16.900 (2)–17.952 (1)
Mus musculus 21.856 (1)–22.515 (2) 9.981 (2)–13.197 (1)
Danio rerio 25.592 (2) 3.278 (2)
D. melanogaster 13.968 (3) 2.539 (3)
C. elegans 20.191 (2) 276 (2)
S. cerevisiae 6.604 (4) 18 (4)
3.1. General Features of Long Non-Coding RNAs
LncRNAs are generally defined as non-coding RNA molecules longer than 200 nucleotides,
a threshold that conventionally distinguishes them from small non-coding RNAs, the other group
of ncRNAs, which includes tRNAs, rRNAs, snRNAs, and snoRNAs, as well as miRNAs, siRNAs,
and piRNAs. LncRNAs share some similarities with mRNAs—they are usually transcribed by RNA
polymerase II, capped with a 7-methylguanosine at the 5′ end, and spliced; most of them are also
polyadenylated at the 3′ end and have their own promoter regions. Differing from protein-coding
mRNAs, most lncRNAs lack an open reading frame (ORF), do not produce detectable peptides [46,47],
and contain fewer exons [47,48].
LncRNAs display low primary sequence conservation compared to both protein-coding genes [49] and
small ncRNAs [50], while they exhibit a high degree of conservation of their secondary structure [51]. Indeed,
the functional role of specific lncRNAs can be preserved despite modest sequence conservation [50,52].
Several human and mouse lncRNAs have consistently been shown to phenotypically rescue the
loss of function of zebrafish homologs, demonstrating functional conservation across species [53].
LncRNAs also have highly conserved splice junction sites [54]. Even more interestingly, the degree of
conservation of their promoter regions is similar to that of coding genes [49]. These highly conserved
promoters bind transcription factors and are subjected to chromatin remodeling events that correlate
with their tissue-specific expression patterns [47,49]. RNA sequence experiments have shown that the
expression of lncRNAs is lower and more tissue- and differentiation-stage-specific when compared to
the expression of protein-coding genes, suggesting that they may have a role in fine modulation of
cell fate and identity, thus providing a fundamental contribution to the formation and functioning
of tissues and organs [55]. This is particularly true for the human brain, which expresses the largest
number of lncRNAs [44].
3.2. Classification and Mechanisms of Action of Long Non-Coding RNAs
The classification of lncRNAs is not an easy task. Various methods to classify them have been
proposed based on their different properties [56]. Typically, lncRNAs are grouped into different
categories according to the relationship between their position and the location of the neighbouring
protein-coding genes, even if peculiar classes of lncRNAs do not fit into this positional classification as
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they present a combination of mentioned features. Based on location, lncRNAs can be classified as:
(1) Long intergenic non-coding RNAs (lincRNAs), defined as lncRNAs that do not overlap annotated
coding genes. LincRNAs represent the largest and most significant group of lncRNAs, constituting
approximately half the overall number of lncRNA [57]. (2) Sense overlapping lncRNAs, which are
transcribed from the sense strand of a protein-coding gene. They may partially or totally overlap with
the protein-coding genes and they can contain exons from protein-coding genes. In some cases, they are
considered isoforms of the protein-coding transcript. (3) Antisense overlapping lncRNAs, also known
as natural antisense transcripts (NATs), which are transcribed from the opposite DNA strand to a
protein-coding transcript with variable degrees of overlap of coding exons. Interestingly, transcriptome
analyses suggest that at least 70% of coding genes have an antisense counterpart [58]. (4) Bidirectional
ncRNAs (bincRNAs), which have a head-to-head orientation with a protein-coding gene and do
not overlap or only partially overlap with its 5′ region. A bincRNA transcript normally exhibits an
expression pattern similar to that of its host gene, suggesting that they may be subjected to common
regulatory mechanisms [59]. (5) Intronic ncRNAs, which are transcribed from the introns of annotated
protein-coding genes in either a sense or antisense direction. MacroRNAs are very long RNAs that
encompass huge genomic distances and numerous genes, or even the whole chromosome [60]. Circular
RNAs (circRNAs) are a class of recently discovered regulatory RNAs produced by back-splicing
circularization of pre-mRNA exons [61]. Circular intronic RNAs (ciRNAs) are created from excised
introns, presenting specific sequences that avoid debranching of the lariat introns. Two other classes of
lncRNAs, the promoter upstream transcripts (PROMPTs) and enhancer-associated RNAs (eRNAs), are
transcribed from gene promoters or enhancers, respectively [62].
A growing number of studies have shown that lncRNAs have a wide spectrum of functions and are
involved in several biological processes, notably differentiation and development [63,64]. They are able
to control gene expression at multiple levels—epigenetic, transcriptional, and post-transcriptional—and
participate in many other important cellular functions, including X-chromosome silencing, genomic
imprinting, and chromatin modification [63,65–67]. This remarkable versatility of lncRNAs is due
to their dual ability to recognize and bind specific DNA or RNA sequences through base-pairing
interactions and to fold into secondary or higher-order structures that mediate their interaction with
proteins. In this way, lncRNAs behave as flexible and modular scaffolds for single proteins or protein
complexes and can guide them to specific DNA or RNA targets. A detailed description of the diverse
mechanisms of action and cellular functions of lncRNAs goes beyond the scope of this review article
(see [68,69] for comprehensive review). LncRNAs can exert their functions in both the nucleus and the
cytoplasm, and their different mechanisms include the modulation of the chromosome architecture,
the control of interactions between distant genomic regions, interaction with chromatin-modifying
complexes, conformation of nuclear domains, activation of transcriptional enhancers, interference
with the transcriptional machinery, and the structural formation and maintenance of nuclear bodies,
such as speckles and paraspeckles. Furthermore, lncRNAs can act at the post-transcriptional level
as regulators of splicing, mRNA decay, protein translation, protein stability, or as decoys or sponges
for miRNAs. This latter function inspired the so-called “competing endogenous RNA (ceRNA)
hypothesis”, according to which coding and non-coding RNAs can crosstalk through their ability to
compete for miRNA binding (with miRNA target sites viewed as the “letters” of a common language),
thus reciprocally influencing their respective expression levels [70].
3.3. Long Non-Coding RNAs in the Central Nervous System: High Versatility and Specificity to the Service of
High Complexity
The human brain, and particularly the cerebral cortex, is undoubtedly the most complex and
sophisticated organ that ever evolved. The correct development of the brain implies a precise
spatiotemporal regulation and a proper balance of pluripotent stem cell proliferation and differentiation
in order to form a spatially rigorous yet dynamic circuitry. A huge number of neurons take part in
these circuits, forming the appropriate synaptic connections. They are also capable of changing these
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synaptic connections and their relative strength over time in response to both internal signals and
external sensory experiences, thus mediating the highest levels of CNS functions, such as cognition
and behavior.
Significantly, the emergence of this complexity and plasticity was paralleled during evolution of
the CNS by the appearance of thousands of new primate-specific or even human-specific lncRNAs.
Indeed, it was calculated that about one-third of human lncRNAs are specific to the primate lineage [47],
hundreds of which seem to be human-specific [71], in stark contrast to the majority of protein-coding
genes expressed in the nervous system, which is highly conserved among mammals [72–74] (see
Table 1). Remarkably, about 40% of the lncRNAs identified in the human genome (corresponding
to 4000–20,000 lncRNA genes) are specifically expressed in the brain, a number which is strikingly
large when considering that the human genome contains a total of about 20,000 protein-coding genes
and around 2300 miRNAs [75], with only a subset of these being specific to the CNS. Additionally,
lncRNAs expressed in the brain show greater spatiotemporal, cell-type, and subcellular expression
pattern specificity than protein-coding genes [76–78], and their expression is dynamically regulated
during development [79–81] in response to neuronal activity [82–84] and during aging [85]. Another
interesting feature of brain-expressed lncRNAs is their preferential genomic position in the proximity of
brain-specific coding genes that are important for transcriptional regulation during CNS development,
often sharing with them a similar expression pattern, indicating that they probably exert an essential
role in fine modulation of the levels of genes that drive neurogenesis [81,86].
The high regulatory versatility of lncRNAs, the high specificity of their expression profile, and the
emergence of new lncRNAs during primate and human evolution probably made these transcripts
crucial actors driving human-specific brain features by enhancing neuronal spatiotemporal gene
regulation, a prerequisite for the brain’s capability to solve complex neurobiological tasks [87].
3.4. Role of Long Non-Coding RNAs in Neuronal Differentiation
Recent functional studies have revealed that a large number of lncRNAs play pivotal roles in
all stages of neuronal differentiation, from pluripotent cells in the early embryo to the terminal cell
types in the mature brain [88]. The underlying regulatory mechanisms are generally based on the
modulation of these lncRNAs by canonical pluripotency transcription factors, such as OCT4, SOX2,
and NANOG; in turn, lncRNAs exert their regulatory functions by directing transcription factors or
chromatin remodeling complexes to lineage-specifying genes [89].
A number of studies using in vitro model systems such as embryonic stem cells (ESCs) or
carried out in vivo in the embryonic mouse brain have demonstrated that several lncRNAs are
involved in establishing pluripotency or driving neural lineage entry. For example, the lncRNA
rhabdomyosarcoma-2-associated transcript (RMST), which is regulated by the transcriptional repressor
RE1-Silencing Transcription factor (REST) and is restricted to the brain, was found to modulate the
differentiation of neural cells in vitro. RMST acts by recruiting the neural transcription factor SOX2 to
key neurogenic genes, such as DLX1, ASCL1, HEY2, and SPS. Accordingly, the loss of RMST can block
the exit from the ESC state and the initiation of neural differentiation [90]. The lncRNA named TCL1
upstream neural differentiation-associated RNA (TUNAR, also known as TUNA) is also able to affect
gene expression in neural cells by a similar mechanism. It can interact with NCL, PTBP1, and hnRNP-K
RNA-binding proteins and direct them to the promoters of neural target genes in differentiating mouse
ESCs. Knockdown of TUNA or each of these three interacting RNA-binding proteins is sufficient
to inhibit neural differentiation [91]. Strikingly, the same functional role is also present in mice and
zebrafish, indicating that the neural lineage commitment driven by lncRNAs is conserved across
relatively distant vertebrates [88]. TUNA and RMST are examples of lncRNAs that can control cell-fate
choice by directing transcription factors and chromatin-remodeling complexes to target loci, allowing
the orchestration of complex gene expression programs by a single lncRNA. It has been proposed that
this is the modus operandi of many lncRNAs during neural differentiation [92]. The lncRNA PNKY
is expressed in the nucleus of dividing neural stem cells (NSCs) in developing mouse and human
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brains, where it acts as a regulator of NSC turnover by controlling the balance between self-renewal
and neuronal differentiation in dividing NSCs. PNKY knockdown leads to an increase in neuronal
differentiation and to the depletion of the NSC population in the embryotic mouse cortex. PNKY
performs this function by regulating the alternative splicing process through the interaction with PTBP1,
an alternative splicing regulator that represses the inclusion of neural exons in non-neural cells [93].
Another lncRNA with a well-established regulatory role in neural development is EVF2 (or DLX6-AS1).
Genetic depletion in EVF2 causes an imbalance of the excitatory to inhibitory neurons in the postnatal
hippocampus and dentate gyrus, owing to the failure of GABAergic interneuron specification, also
leading to reduced synaptic inhibition [94]. EVF2 acts by recruiting the DLX transcription factor and
methyl CpG-binding protein MECP2 to regulatory regions controlling the expression of interneuron
lineage genes (including DLX5, DLX6, and GAD1) needed for GABAergic interneuron specification in
the developing mouse forebrain [94,95]. The intergenic lncRNA linc-BRN1B controls the differentiation
of delaminating neural progenitor cells in vivo. Deletion of the linc-BRN1B locus results in significant
loss of upper cortical layers and of the expression levels of POU3F3, a transcription factor implicated
in neuronal development. This reduction originates with loss of basal cortical progenitors, which
subsequently drives precocious migration and differentiation of lower layer neurons [96]. GOMAFU
(also known as MIAT, myocardial infarction associated transcript) is a lncRNA expressed in the nucleus
of dividing NSCs and differentiating neurons. It modulates the alternative splicing of several neuronal
genes, including the schizophrenia-associated genes DISC1 and ERBB4, likely through the interaction
with the splicing factors SF1, SRSF1, and QKI [84,97]. Depletion of GOMAFU in embryonic mice leads
to increased amacrine cell and Muller glia differentiation [98], as well as an improperly regulated
transition of actively dividing ventricular zone progenitor cells into differentiating neurons as they
migrate outward into the cortical plate [81].
Altogether, these findings point to lncRNAs as key regulators of neural cell fate specification
and stem cell turnover during brain development by conducting lineage-specific gene expression
programs [88].
3.5. Role of Long Non-Coding RNAs in Neurite Elaboration and Synaptogenesis
LncRNAs are also implicated in neurite outgrowth and synaptogenesis, which are critical stages
during brain development in order to establish the connections required for normal brain function [88].
An antisense lncRNA, BDNF-AS, which transcribes antisense to the BDNF growth factor gene, can
control neurite elaboration during development through the regulation of local gene expression.
Indeed, inhibition of BDNF-AS resulted in an increase in BDNF protein levels, which was associated
with reduced EZH2 recruitment and altered chromatin state at the BDNF locus. The resulting BDNF
overexpression then drove elevated neuronal outgrowth, differentiation, survival, and proliferation,
both in vitro and in vivo [99]. The first lncRNA that was found to be involved in the regulation
of synaptogenesis is BC1/BC200 (also named BCYRN1, brain cytoplasmic RNA 1). BC1/BC200 is
expressed in the developing and adult CNS, where it is actively trafficked to dendrites [100]. There,
it interacts with FMRP and the translational machinery, where it represses local translation in the
synapse [101]. Through this mechanism, BC1/BC200 regulates spatially restricted synaptic turnover
in vivo [102–104]. The lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is
abundantly expressed in neurons and is enriched in nuclear speckles in a transcription-dependent
manner. MALAT1 has been shown to recruit Ser/Arg (SR) family splicing proteins to transcription sites
with the aim of controlling the expression of synaptogenesis-associated genes in cultured hippocampal
neurons. Moreover, knockdown of MALAT1 in this system reduces synaptic density levels, while its
overexpression increases synaptic density [105]. These data suggest that MALAT1 is able to regulate
synaptogenesis by modulating synapse formation or maintenance genes via a mechanism involving
splicing modulation via tethering splicing factors to nuclear speckles.
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3.6. Role of Long Non-Coding RNAs in Neuronal and Synaptic Plasticity
LncRNAs are also involved in the regulatory mechanisms that govern synaptic plasticity and
strength. Synaptic plasticity plays an important role in learning and memory processes. The learning
process in embryonic and adult brains depends on normal development of a correct balance between
excitatory glutamatergic and inhibitory GABAergic neurons in the hippocampus. As mentioned before,
the EVF2 lncRNA is essential for the development of GABAergic neurons, as it regulates their gene
expression in the developing brain. Accordingly, EVF2 silencing has been shown to cause abnormal
formation of GABAergic circuits in the hippocampus and dentate gyrus, hence leading to abnormal
synaptic activity in mice [94]. Translational control of local protein synthesis represents another crucial
process underlying synaptic plasticity. As previously noted, the BC1/BC200 lncRNA is transported
to synapses, where it represses local translation. Importantly, BC1/BC200 expression is dynamically
upregulated in synapses in response to increased neuronal activity [106], thus modifying the protein
composition of synapses with a negative feedback mechanism. Interestingly, knockout of BC1/BC200 in
mice produces neuronal hyperexcitability and behavioral phenotypes, including increased anxiety and
exploratory behavior defects [102–104]. Altogether, these data indicate that the translational control
exerted by BC1/BC200 is essential for neuronal plasticity and its loss causes abnormal neuronal activity
and behavioral defects. Alterations in the subunit stoichiometry of ion channels may also influence
neuronal excitability and plasticity by affecting action potential thresholds. An example is provided by
potassium voltage-gated channel subfamily A member 2 (KCNA2), a major potassium channel subunit,
whose expression is regulated by the overlapping antisense RNA KCNA2-AS in response to peripheral
nerve injury and in neuropathic pain [107]. The expression of KCNA2-AS is strongly induced by
myeloid zinc finger 1 (MZF1) transcription factor in dorsal root ganglia (DRG) rat neurons upon nerve
injury and its overexpression leads to a selective reduction of KCNA2 levels. In turn, this reduces the
total voltage-gated potassium current and increase neuronal excitability, causing mechanical and pain
hypersensitivity. These results show that KCNA2-AS is able to respond to peripheral nerve damage
by altering synaptic plasticity. Interestingly, downregulation of another well characterized lncRNA,
nuclear paraspeckle assembly transcript 1 (NEAT1), leads to changes in the expression of several genes
involved in ion channel function following neuronal activation, as discussed below [108]. Another
gene negatively regulated by an overlapping antisense RNA is BDNF, whose expression is repressed
by BDNF-AS, as mentioned before. BDNF controls synaptic maintenance or elimination, depending
on activity levels. Interestingly, expression of BDNF-AS is activity-dependent [83,99] and it has been
hypothesized that it may control synaptic turnover and neuronal plasticity by coupling neuronal
activity to BDNF expression [88]. Other lncRNAs have been proposed to couple neuronal activity and
synaptic plasticity to alternative splicing of specific genes. For example, GOMAFU has recently been
shown to modulate alternative splicing of DISC1 and ERBB4 [84], as already mentioned. Since deletion
of Erbb4 in mice enhances LTP in the hippocampus, GOMAFU-regulated splice isoforms of this gene
may affect normal synaptic plasticity. Also, knock-down and overexpression of MALAT1, which is
able to recruit different splicing factors, can reduce and increase synaptic density, respectively [105].
4. LncRNAs and Neuropsychiatric Disorders: The Three Musketeers in the Synapse—GOMAFU,
NEAT1, and MALAT1
Some studies have already shown thorough modifications of lncRNAs expression within the brain
of neuropsychiatric patients [84,109]. These studies outlined that lncRNAs are profoundly altered
whenever normal neurophysiological processes are modified, suggesting that in conditions of altered
neuronal physiology, lncRNA modulation could represent both a benign attempt to functionally
adapt to an unbalanced condition or contribute to pathology development (Figure 1). In the second
eventuality, multiple genetic factors alone or in combination with environmental challenges that
modify the biology of lncRNAs in terms of expression or cellular localization could involve this class
of epigenetic regulators as downstream pathologic effectors.
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Figure 1. LncRNAs and their potential roles as disease modifiers in psychiatric disorders. Genome
per environment (GxE)-related etiologic causes of mental illness entail molecular dysfunctions
(endophenotypes) that impact synaptic function and cause a cluster of recurrent symptoms within
different pathologic forms. The three better studied lncRNA, namely GOMAFU, NEAT1, and MALAT1,
are implicated as disease-relevant factors. They could participate in pathologic manifestations directly,
playing a role in pathophysiology, or could act as disease modifiers whose targeted modulation may
represent a potential new strategy to ameliorate symptomatology. LncRNAs (Long non-coding RNAs);
DISC locus (Disrupted in Schizophrenia locus); SNP (Single Nucleotide Polymorphism); HPA axis
(Hypothalamic-Pituitary-Adrenal axis).
There is evidence that clearly implicates lncRNAs as part of the mechanisms involved in neuronal
activity responses. In particular, their covariation of expression with the immediate early genes (IEGs)
suggests an important involvement in neuroplasticity through synaptic tuning, consequently displaying
the ability to impinge on circuitry excitability. The fact that lncRNAs are thoroughly modified in the
post-mortem brain from neuropsychiatric patients is consistent with the widely accepted—albeit still
to be fully demonstrated—neuroplasticity hypothesis of neuropsychiatric disorders. Within this frame,
we now discuss several examples of experience-driven lncRNA modulation and the roles of lncRNAs
as possible behavioral modifiers through the regulation of synaptic physiology.
4.1. GOMAFU—Anxiety Modifying lncRNA
GOMAFU (MIAT) represents a unique and remarkable example of well-investigated brain-relevant
lncRNA. Indeed, GOMAFU’s role in neuropsychiatric disorders was proven through multidisciplinary
approaches coupling clinical investigations—with reported deregulation in human post-mortem
cortices of SCZ patient—to convincing basic science indicating activity-dependent behavior of this
lncRNA [84,110]. GOMAFU levels decrease in response to neuronal activation, both in vitro and in vivo.
Indeed, KCl-induced depolarization of mouse primary cultured neurons and human iPSC-derived
neurons, together with induction of neuroplasticity-related programs of gene expression, also entails
transient GOMAFU downregulation. Many brain areas involved in stress response, including the
hippocampus, medial prefrontal cortex, and the amygdala, undergo rapid circuitry activation when
a stressful paradigm is experienced. A widely used stressful learning paradigm in rodents involves
fear conditioning. In this trial, a conditioned stimulus (CS, which can be the context cage, a sound,
or a light) is followed by the unconditioned stimulus (US, the foot shock). This paradigm, entailing a
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training phase of repeated CS+US, has been widely used to assess associative memory consolidation
between US and CS. However, as it represents a highly traumatic experience that also increases anxiety,
it can be employed to monitor the molecular basis of stress response and anxiety arousal. Interestingly,
fear conditioning (CS+US training), but not CS alone, significantly decreases GOMAFU expression in
the mouse medial prefrontal cortex. Notably, from a behavioral point of view, GOMAFU knock-down,
obtained by antisense oligonucleotides stereotaxically infused into the mPFC, is able to modify the
basal level of anxiety [110]. It has been proposed that GOMAFU negatively controls a program of
gene expression via a cis-mediated mechanism, including the Crybb1 gene, which is involved in
sustaining anxiety. The proposed epigenetic mechanism entails GOMAFU-mediated recruitment of
polycomb repressive complex 1 (PRC1), and in particular its component BMI1, in the Crybb1 promoter.
In this regard, transient GOMAFU downregulation in response to anxiety-inducing trials such as fear
conditioning could allow timely expression of genes whose transcription promotes increased vigilance
and adaptive fear manifestation. However, this pro-anxiety transcriptional program should be limited
within the duration of threatening or dangerous experiences. In this regard, SCZ patients, experiencing
excessive, decontextualized expression of fear and anxiety underlying delusional disorders of the
persecutory type, also show GOMAFU-stable downregulation [84]. GOMAFU knock-out mice were
recently generated [111]. Interestingly, they did not display obvious morphological or physical
differences to wild-type littermates, suggesting that this kind of mutation does not impact core
biological processes. An interesting peculiarity of GOMAFU knock-out mice, however, is represented
by hyperlocomotion behavior, which is not associated with emotional or affective issues but still
represents a feature that has to be taken into consideration, given that rodent pharmacological models
of SCZ display the same phenotype.
At this point, (i) GOMAFU stress-dependent downregulation, (ii) its facilitating role in pro-anxiety
transcriptional program, and (iii) its stably reduced expression in SCZ post-mortem cortices strongly
support the hypothesis of an important pathogenic role of GOMAFU in SCZ.
In further support of GOMAFU’s role in SCZ pathogenesis, considering GOMAFU’s function as a
splicing regulator, overexpression of GOMAFU in human iPSC-derived neurons leads to significantly
decreased levels of disrupted on schizophrenia 1 (DISC1), one of the most important loci associated
with the disorder, along with DISC1 splicing isoforms Esv1, d3, and d7/8. Conversely, GOMAFU
knock-down only increases DISC1 expression but not expression of its unspliced transcripts, another
characteristic that is almost perfectly recapitulated in the SCZ post-mortem brain [84].
4.2. NEAT1—Excitability Modifying lncRNA
Nuclear-enriched abundant transcript 1 (NEAT1) belongs to a family of lncRNAs displaying
considerable enrichment in the mammalian brain [112]. NEAT1 represents a critical scaffolding
component and structural determinant of paraspeckles [113], subnuclear structures that are involved
in many cellular functions, including splicing and transcriptional modulation through the modification
of the chromatin structure [112]. Similarly to GOMAFU, NEAT1 also displays an aberrant pattern
of expression in SCZ-patient-derived post-mortem specimens, in particular at the cortical level,
where NEAT1 is significantly decreased in 14 subareas of the cerebral cortex [109], and also in
the hippocampus, caudate, and putamen. Interestingly, the decrease of NEAT1 is independent on
antipsychotic medications, as patients who suspended the therapy from 4 weeks to 7 years prior to
death did not show significant differences of NEAT1 downregulation compared to treated patients.
Notably, knock-out mice have been generated lacking the NEAT1 gene [114]. These mice are viable and
fertile, and they do not display prominent histopathological modifications, except that they completely
lack paraspeckles, suggesting that at least in resting conditions these subnuclear structures and their
essential component NEAT1 are dispensable [114]. It was reported that NEAT1 plays an important role
in unfolded protein response, as its levels significantly increased after a specific cellular challenge, i.e.,
proteasomal inhibition [113]. A possible interpretation is that NEAT1KO mice could display specific
vulnerability to cellular or environmental stress [114], a hypothesis that has not yet been explored.
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Interesting suggestions of NEAT1’s implications in neurophysiology have been recently observed in
in vitro and in vivo studies. NEAT1 follows GOMAFU’s trend in the SCZ post-mortem brain. Similarly
to GOMAFU, NEAT1 expression is sensitive to neuronal activation. Indeed, KCl-induced depolarization
of human induced pluripotent stem cell (iPSC)-derived neurons rapidly and transiently elicits NEAT1
downregulation. RNA immunoprecipitation technique showed interaction of NEAT1 with KCNAB2
and KCNIP1 in SH-SY5Y cells. These modulatory proteins aim to decrease neuronal excitability,
buffering excessive synapse depolarization, a behavior that is also engaged upon KCl-induced neuronal
activation [108]. Thus, a picture emerges in which an activity-dependent decrease of NEAT1 levels
could be involved in free protein interactors, allowing nuclear-cytoplasmic shuttling of KCNAB2
and homeostatic enhancement of potassium channel activity, aiding the shut-off of synapses [108].
Importantly, NEAT1 downregulation is also acutely promoted in rats with pharmacological epilepsy
with two different chemo-convulsant compounds (pilocarpine and kainic acid). These two models of
temporal lobe epilepsy act by increasing glutamatergic neurotransmission in temporal brain areas.
Interestingly, upon chronic epileptogenic stimulation, NEAT1 levels become unresponsive to neuron
hyperexcitation, increasing the risk of seizure activity [108]. From these data, the authors draw a clear
implication of acute downregulation of NEAT1 levels in hyperexcitability protection, which is lost
upon reiterated engagement of such a process and is highly consistent with increased NEAT1 levels in
the brains of patients affected by intractable seizures [108]. If we take into consideration the seemingly
counterintuitive observation that antisense oligonucleotide (ASO)-mediated NEAT1 downregulation
increases neuronal excitability in vitro [108], possibly through scaling-up of homeostatic synapses, we
could depict a possible role of NEAT1 downregulation in the homeostatic synaptic scaling-up of SCZ
patients with increased cortical circuitry over-excitability. Alternatively, it is also possible that in a
complex in vivo circuital context such as the human cortex, NEAT1 downregulation may be uncoupled
from mechanisms of homeostatic plasticity; in this second scenario, NEAT1 deregulation could be
instrumental in decreasing cortical excitability. Interestingly, both these scenarios are compatible with
disrupted predictive sensing, a core symptom of neuropsychiatric disorders [11,12,36].
4.3. MALAT1—Neuroplasticity Modifying lncRNA
Until now we have described literature data involving coupling molecular lncRNA-related
modifications—which are associated or even causally linked to interesting endophenotypes in
terms of neuronal excitability and behavior—with clinical data showing that the same lncRNAs,
namely GOMAFU and NEAT1, undergo thorough deregulation in the schizophrenic brain. Notably,
another lncRNA, MALAT1, which displays considerable expression in neurons, can be linked
thanks to rodent models of SCZ to the set of molecular alterations contributing to disease onset
and progression. The SCZ-like phenotype can be effectively induced by chronically inhibiting the
ionotropic glutamate receptor NMDAR with open-pore blockers, including MK-801 and ketamine.
Interestingly, such models also work in humans and non-human primates, which substantially enhances
their validity. Indeed, chronic inhibition of the NMDAR reproduces core SCZ-like traits (such as
hallucinations and negative symptoms, which are clearly not easily measurable in rodents), cognitive
deficits [115], and well-known SCZ endophenotypes in terms of gamma oscillation disruption, both in
rodents and primates [116]. In rodents, a behavioral marker of SCZ-like acquired symptomatology
is increased locomotor activity, which is also induced by methamphetamine and amphetamine
activation of dopaminergic receptors, similarly impacting gamma oscillation and representing similar
pharmacological models of SCZ. Remarkably, both chronical MK-801-mediated inhibition of NMDAR
and methamphetamine administration, along with inducing core SCZ symptomatology in mice, also
cause lncRNA modification that is highly reminiscent of modifications observed in the SCZ human
brain [115–117]. Indeed, these two treatments induce significant downregulation of GOMAFU, a clear
trend toward decreased NEAT1, and a strong decrease in MALAT1 [117]. We previously focused our
attention on neuronal activity-dependent covariation of widely known neuroplasticity-related genes
(in particular the IEGs) and lncRNAs. In this regard, MALAT1 represents an eminent example of
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activity-modulated lncRNA, whose transcriptional induction mechanism interestingly retraces those
of the IEGs. These genes respond to neuronal activation with a peculiar fast-track-like epigenetic
mechanism recently described by Li Huei Tsai’s group [118], which is aimed at instant transactivation
that perfectly matches stimuli perception. It has been referred to as the double-strand brake (DSB) of
gene promoters. This mechanism utilizes the DNA double-strand brake as a way of speeding up RNA
pol2 processivity, resolving the topological constraints of double-helix DNA. MALAT1 follows the
same DSB-accelerated transactivation process. These data suggest that the peculiar fast kinetic nature
of MALAT1 transcriptional response in neurons is related to a stimuli-processing role in neuroplasticity.
Considering that lncRNAs are ready-to-use molecules, neurophysiology changes upon experience
might, at least theoretically, be primed by MALAT1.
Notably, all three lncRNAs belong to the class of lincRNAs (defined as lncRNAs which do not
overlap with coding regions), reasonably having a multitarget “trans” effect, as witnessed by their
pleiotropic activity.
5. Concluding Remarks
In conclusion, the complex nature of modified lncRNA transcriptomes must include relevant
genes: (i) with pathogenic implications, participating to disease onset and progression; (ii) with
homeostatic properties, such as those lncRNAs whose variation represents an attempt to counteract
pathophysiology; or (iii) neutral with respect to the disease. We strongly believe that the role of lncRNAs
in neuroplasticity modulation endows many post-mortem transcriptional studies with a novel role of
interpretation involving at least those lncRNAs species that undergo activity-induced modulation.
The role of lncRNAs in psychiatric disorders has just started to be investigated, and we can
now only outline their functional implications in pathology onset and progression. For instance,
the observations made in schizophrenia research could be extended to other neuropsychiatric disorders
in the context of the ever-growing idea of a continuum among these pathologies [9].
In general, the numbers of protein coding genes, as well as their functions, are comparable
from lower to higher eukaryotes. On the contrary, lncRNAs are highly specific to primate lineages
and the majority of them are restricted to neurons. This context sheds light on the role of lncRNAs
in driving the evolution of brain complexity. It seems that neuropsychiatric disorders are peculiar
to mammals, specifically those species enriched in lncRNAs. As all multicellular organisms have
nervous systems and neurons, the further layer of regulation in lncRNAs fuels an extraordinary
emergent nature that is not instrumental to the biological processes but is involved in finely shaping
the highest mental functions. Nonetheless, the higher the inherent complexity, the more potential
issues. Luckily, in circumstances of fine circuity disruption (or probably by their virtue), humans are
able to create extraordinary art and make amazing technological and scientific discoveries. In other
words, as Randolph Nesse recently argued, “there must be a good reason for bad feelings” [119].
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